Treatment strategies for the developing world
|
|
- Donald Day
- 5 years ago
- Views:
Transcription
1 David A Cooper National Centre in HIV Epidemiology and Clinical Research The University of New South Wales Sydney, Australia
2 First line standard of care First line in the developing world First line failure Second line Three class failure
3 Fauci Nature Medicine 2003 First line standard of care Targets for anti-hiv drugs
4 First line standard of care FEI N(t)RTI NNRTI PI ENF Current drugs and classes AZT ddi ddc d4t 3TC ABV TFV FTC NVP DLV EFV SQV RTV IDV NFV APV LPV/r ATV fapv TPV DRV
5 DHHS Guidelines, 2004 First line standard of care Recommended regimens for treatment-naive naive patients: DHHS guideline preferred regimens + or + or + or + EFV LPVr 3TC FTC AZT TFV
6 First line standard of care 100 Gilead 903: week 144 efficacy intent to treat 80 % patients with HIV-1 60 RNA < 50 c/ml 40 TDF + 3TC + EFV d4t + 3TC + EFV 73% 69% weeks Gallant et al, 2004
7 First line standard of care Gilead 903: total limb fat kilograms TFV+3TC+EFV d4t+3tc+efv 0 96 weeks 144 TDF + 3TC + EFV d4t + 3TC + EFV Gallant et al, IAC
8 Gallant et al, NEJM 2006 First line standard of care Gilead 934: virologic efficacy 100 % 80 responder proportion with HIV-RNA <50 c/ml (TLOVR) n = 487 TFV+FTC 80%* CBV 70%* *95% CI: (+1.6%, +16.6%); p = BL week
9 First line standard of care 2NN: treatment success and failure % of patients NVP-qd NVP-bd EFV NVP+EFV failure component: (whichever comes first) change Rx disease progression virologic success VL <50 c/ml success: only significant difference: EFV vs NVP+EFV, p< 0.001
10 First line standard of care 2NN: grade 3 or 4 laboratory toxicities % NVP-qd n=220 NVP-bd n=387 EFV n=400 NVP+EFV n=209 p hepatobiliary lab. toxicity * non-hepatobiliary lab. toxicity neutropenia amylase triglycerides alkaline phosphatase hepatobiliary: only significant difference: NVP-qd vs EFV, p< * elevated AST and/or ALT
11 First line standard of care 1.0 ACTG 5142: time to virologic failure 0.8 proportion not 0.6 failed adjusted p values LPV/EFV vs LPV 0.13 LPV/EFV vs EFV 0.5 LPV vs EFV EFV LPV/EFV LPV proportion not failed - week 96 LPV/EFV 73% LPV 67% EFV 76% number at risk time in weeks from randomisation LPV/EFV LPV EFV Ridler et al, WAC 2006
12 First line standard of care PI SQV r IDV NFV APV LPV/r ATV fapv TPV DRV Protease inhibitors - unboosted poor bioavailability complex regimens high pill burden unpredictable efficacy hard to manage toxicity signature resistance common
13 First line standard of care Protease inhibitors PI SQV/ r IDV - unboosted biovailability improved by ritonavir boosting NFV APV LPV/r ATV/ fapv/ TPV DRV less complex regimens lower pill burden more predictable efficacy less toxicity negligible resistance in naive patients
14 Walmsley et al, NEJM 2002 First line standard of care M98-863: 863: LPVr versus NFV - efficacy % 40 patients * 75 *P<0.001 * baseline characteristics n = % male mean age, yr CD4+, median HIV RNA, median (logs) <400 cp/ml <50 cp/ml HIV RNA at 48 weeks d4t/3tc/lpvr d4t/3tc/nfv
15 First line standard of care SQV IDV RTV NFV LPV fapv ATV TPV gastrointestinal lipodystrophy ? hepatitis nephrolithiasis paresthesias bilirubin ++ retinoid effects + rash Side-effect effect profile of protease inhibitors + asthenia drug causes toxicity ++ main toxicity Bartlett JG, Medical Management of HIV Infection, JHUSM, 2002
16 First line standard of care First line in the developing world First line failure Second line Three class failure
17 Gilks et al, Lancet 2006 First line in the developing world WHO recommended first-line regimens Standard first-line regimen NRTIs NNRTI AZT or d4t or TFV or ABV and 3TC or FTC and EFV or NVP Triple NRTI regimen NRTIs AZT or d4t and TFV or ABV and 3TC or FTC
18 Beck et al, AIDS 2006 First line in the developing world National guidelines: criteria for starting ART number of countries % clinical + CD4 or TLC 33.3% clinical + CD4 WHO clinical staging clinical +TLC CD4 only clinical and laboratory criteria CD4 < 200 and consider < 350 TLC < % 11.1% 5.6% clinical only
19 Beck et al, AIDS 2006 First line in the developing world National guidelines: major first-line regimens number of countries % 54% 24 countries reported that d4t + 3TC + NVP is the preferred first-line antiretroviral regimen 37% 26% 4 0 d4t + 3TC + NVP AZT + 3TC + NVP AZT + 3TC +EFV d4t + 3TC + EFV
20 First line standard of care First line in the developing world First line failure Second line Three class failure
21 First-line failure Causes of treatment regimen failure baseline patient factors suboptimal adherence and missed clinic appointments drug side-effects and toxicity pharmacokinetics potency of the ART regimen
22 First-line failure age year of starting therapy pretreatment HIV RNA level pretreatment CD4 cell count prior AIDS illness Baseline patient factors comorbidities (e.g. depression) active substance use baseline drug resistance prior ART with drug resistance or cross resistance
23 First-line failure TAHOD: first antiretroviral treatment 100% 80% 60% 40% 20% 0% <= d4t/3tc/nvp 3 or more ARV with NNRTI, no PI (other than d4t/3tc/nvp) 3 or more ARV with PI, no NNRTI 3 or more ARV, NRTI only mono/double ARV n=
24 First-line failure TAHOD: duration on first antiretroviral treatment year after ARV started d4t/3tc/nvp 3 or more ARV with NNRTI, no PI (other than d4t/3tc/nvp) 3 or more ARV with PI, no NNRTI 3 or more ARV, NRTI only mono/double ARV
25 First-line failure Virological failure incomplete virological response <400 copies/ml by 24 weeks virologic rebound
26 First-line failure Clinical and immunological failure failure to increase cells/µl above baseline CD4+ cell count over first year decrease to below baseline CD4+ cell count on therapy occurrence or recurrence of HIV-related events after at least 3 months on HAART
27 First-line failure TAHOD: factors associated with treatment change patients follow up events p n= (years) n= rate HR (95% CI) value total hemoglobin level prior to treatment normal anemia ( ) not tested ( ) hemoglobin tested within 180 days before ART started. normal anemia male Hb > 13g/dl Hb 8-13g/dl female Hb > 12g/dl Hb 8-12g/dl
28 First-line failure reason for treatment change n= (%) days on treatment median (range) stop treatment permanently n= (%) number of patients 131 (100) 262 (2-1519) 15 (11.5) adverse effect 82 (62.6) 295 (2-1519) patients decision/ request TAHOD: reasons for treatment change 2 (2.4) 18 (13.7) 196 (6-1005) 7 (38.9) treatment failure 5 (3.8) 457 ( ) 0 (0.0) clinical progression/ hospitalisation 3 (2.3) 85 (34-322) 1 (33.3) compliance difficulties 2 (1.5) 136 (9-262) 0 (0.0) other 18 (13.7) 250 ( ) 4 (22.2) not reported 3 (2.3) 211 (88-545) 1 (33.3)
29 First-line failure TAHOD: treatment change due to adverse effects reason for treatment change days on treatment stop treatment permanently n= (%) median (range) n= (%) adverse effect 82 (62.6) 295 (2-1519) 2 (2.4) lipodystrophy 26 (31.7) 546 ( ) 0 (0.0) hepatitis 10 (12.2) 28 ( ) 0 (0.0) rash 12 (14.6) 14 (10-108) 0 (0.0) peripheral neuropathy 9 (11.0) 407 ( ) 0 (0.0) lactic acidosis 6 (7.3) 416 ( ) 0 (0.0) pancreatitis 5 (6.1) 55 (5-343) 1 (20.0) nausea and vomiting 4 (4.9) 18 (2-49) 0 (0.0) fever 2 (2.4) 19 (11-27) 0 (0.0) allergy 1 (1.2) 61 0 (0.0) insomnia 1 (1.2) 42 0 (0.0) missing 6 (7.3) 68 (21-491) 1 (16.7)
30 First line standard of care First line in the developing world First line failure Second line Three class failure
31 Gilks et al, Lancet 2006 Second line WHO recommended second-line regimens Second-line regimen if standard first-line used NRTIs PI ddi or TFV and ABV or 3TC and PI/r with/without AZT Second-line regimen if triple NRTI used NRTIs PI NNRTI ddi and PI/r and EFV or NVP
32 Second line Gilead 903: development of resistance mutations through week 144 (ITT) TFV+3TC+EFV(n=299) d4t+3tc+efv (n=301) n % of total % of failures n % of total virologic failures % % % of failures any EFV-R* % 55% % 49% any M184V/I % 38% % 35% any K65R 8 2.7% 17% 2 0.7% 4% other NRTI 1 0.3% 2% 4 1.3% 8% wild-type or as baseline % 38% % 47% *EFV-R = efavirenz resistance Miller et al, IAC 2004
33 Second line Regimens for first failure in developing world initial regimen predicted resistance pattern recommended change d4t/3tc/nvp M184V ± NNRTI mutation ddi/tfv + ABV/3TC + PI/r ± AZT 3NRTIs TAMs M184V NNRTI + PI/r ± ddi
34 Second line National guidelines: major second-line regimens number of countries 16 42% % 27% 24% 21% 4 0 ABV + ddi + LPVr ABV + ddi + NFV ABV +ddi + SQVr TFV + ddi + LPVr TFV + ddi + NFV Beck et al, AIDS 2006
35 First line standard of care First line in the developing world First line failure Second line Three class failure
36 Three class failure PLATO: CD4+ decline with MDR versus wild-type HIV CD4+ slope 0 (cells/year) -50 untreated WT (n=205) treated MDR (n=628) < ,000- >30,000 10,000 30,000 steady state viral load (copies/ml) Lancet 2004
37 Three class failure E-184V: 3TC monotherapy with 3TC resistant virus mean HIV-RNA change log 10 copies per ml mean CD4% change mean CD4+ T-cell change cells/μl TC mono TI p= p= p= weeks Castagna et al, AIDS 2006
38 Three class failure Partial treatment interruptions (n= 53) 1.0 week 2 change in VL change in plasma HIV RNA NRTI PI NNRTI ENF discontinued treatment class residual activity against 'resistant' variant: NRTIs >> > ENF, PI > NNRTI
39 Summary: treatment/virus factors despite emergence of drug-resistance, plasma HIV RNA levels can remain below the off-treatment setpoint for years as long as treatment is maintained persistent anti-hiv activity against drug-resistant virus NRTIs >> PI > NNRTIs reduced replicative capacity PI mutations, M184V > NNRTI mutations
40 presentation by by Dorrie Cooper Instructional designer
41 see you in Sydney July 2007 Australia has been at the leading edge of HIV research since the early days of the epidemic. It is a privilege for us to welcome our colleagues and friends to the beautiful city of Sydney, for the first IAS meeting to be held in this country. David Cooper, Local Conference Chair in partnership with
Management of Treatment-Experienced Patients: New Agents and Rescue Strategies. Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine
Management of Treatment-Experienced Patients: New Agents and Rescue Strategies Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine When to Modify Therapy! Studies to date show better responses
More informationComprehensive Guideline Summary
Comprehensive Guideline Summary Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents AETC NRC Slide Set Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and
More informationMDR HIV and Total Therapeutic Failure. Douglas G. Fish, MD Albany Medical College Albany, New York Cali, Colombia March 30, 2007
MDR HIV and Total Therapeutic Failure Douglas G. Fish, MD Albany Medical College Albany, New York Cali, Colombia March 30, 2007 Objectives Case study Definitions Fitness Pathogenesis of resistant virus
More informationTreatment experience in South Africa. Dr Ian Sanne Clinical HIV Research Unit University of the Witwatersrand
Treatment experience in South Africa Dr Ian Sanne Clinical HIV Research Unit University of the Witwatersrand Overview South African Prevalence Adherence Combination ddi + d4t Nevirapine Hepatotoxicity
More informationHIV Treatment: New and Veteran Drugs Classes
HIV Treatment: New and Veteran Drugs Classes Jonathan M Schapiro, MD National Hemophilia Center Stanford University School of Medicine Rome, March 2013 Overview Many excellent antiretroviral agents are
More informationHIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University
HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start
More informationANTIRETROVIRAL TOXICITY Strategies for prevention and treatment
ANTIRETROVIRAL TOXICITY Strategies for prevention and treatment Francisco Antunes Professor da Faculdade de Medicina da Universidade de Lisboa e Director do Serviço de Doenças Infecciosas do Hospital de
More informationJosep Mallolas Hospital Clínic Barcelona
Nuevos paradigmas en la infección VIH Josep Mallolas Hospital Clínic Barcelona 1. Do you believe, I have to start ARV therapy? Incidence and Mortality of AIDS in Spain HIV and NON-AIDS complications HIV
More informationManagement of patients with antiretroviral treatment failure: guidelines comparison
The editorial staff Management of patients with antiretroviral treatment failure: guidelines comparison A change of therapy should be considered for patients if they experience sustained rebound in viral
More informationAntiretroviral Treatment Strategies: Clinical Case Presentation
Antiretroviral Treatment Strategies: Clinical Case Presentation Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan Chia-Jui, Yang M.D Disclosure No conflicts of interests.
More informationSomnuek Sungkanuparph, M.D.
HIV Drug Resistance Somnuek Sungkanuparph, M.D. Associate Professor Division of Infectious Diseases Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University Adjunct Professor
More informationThe Eras of the HIV Epidemic
The Eras of the HIV Epidemic 1930-1980 1981-1986 1987-1995 1996-2005 2nd Gen. HAART 2006-2011 2006: Disproportionate distribution of HIV 2006: Gates and Clinton at International AIDS conference announce
More informationClinical support for reduced drug regimens. David A Cooper The University of New South Wales Sydney, Australia
Clinical support for reduced drug regimens David A Cooper The University of New South Wales Sydney, Australia Clinical support for reduced drug regimens First line optimisation Virological failure New
More informationContinuing Education for Pharmacy Technicians
Continuing Education for Pharmacy Technicians HIV/AIDS TREATMENT Michael Denaburg, Pharm.D. Birmingham, AL Objectives: 1. Identify drugs and drug classes currently used in the management of HIV infected
More informationThe use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines
The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines I. Boucoiran, T. Lee, K. Tulloch, L. Sauve, L. Samson, J. Brophy, M. Boucher and D. Money For and
More informationThe next generation of ART regimens
The next generation of ART regimens By Gary Maartens Presented by Dirk Hagemeister Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN KAAPSTAD Current state
More information13 th Conference on Retroviruses and Opportunistic Infections (CROI)
REPORT FROM 13 th Conference on Retroviruses and Opportunistic Infections (CROI) February 5 8, 5 2006 Denver, CO 1 Tipranavir Significantly Reduces Concentrations of Other ARVs -10 % change PK -30-50 -70-68
More informationSwitching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches
Switching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches Harry W. Lampiris, MD Chief, Infectious Disease Section, San Francisco VA Medical Center Professor
More information12th European AIDS Conference / EACS ARV Therapies and Therapeutic Strategies A CME Newsletter
EACS 2009 11-14, November 2009 Cologne, Germany Course Director Jürgen K. Rockstroh, MD Co-Chairman, 12th European AIDS Conference Professor, University of Bonn Bonn, Germany Faculty Calvin Cohen, MD,
More informationManagement of NRTI Resistance
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Management of NRTI Resistance David Spach, MD Principal Investigator, NW AETC Professor of Medicine, Division of Infectious Diseases University of Washington
More informationUpdate on Antiretroviral Treatment for HIV Infection 2008
Update on Antiretroviral Treatment for HIV Infection 2008 Janet Gilmour MD FRCP(C) Clinical Associate Professor of Medicine University of Calgary November 2008 Disclosure and Acknowledgements Disclosure:
More informationSTRIBILD (aka. The Quad Pill)
NORTHWEST AIDS EDUCATION AND TRAINING CENTER STRIBILD (aka. The Quad Pill) Brian R. Wood, MD Medical Director, NW AETC ECHO Assistant Professor of Medicine, University of Washington Presentation prepared
More informationSecond-Line Therapy NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Second-Line Therapy David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases University of Washington Presentation
More informationMedscape's Antiretroviral Pocket Guide for the Treatment of HIV Infection
Table 3. Characteristics of Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Generic Name (Abbreviation) / Trade Name Abacavir (ABC) / Ziagen Trizivir with ZDV + 3TC Epzicom with 3TC Didanosine (ddi)
More informationKiat Ruxrungtham. Professor of Medicine Chulalongkorn University, and HIV-NAT, Thai Red Cross AIDS Research Centre
Kiat Ruxrungtham Professor of Medicine Chulalongkorn University, and HIV-NAT, Thai Red Cross AIDS Research Centre www.iasusa.org; www.aidsinfo.nih.gov; www.clinicaloptions.com; www.clinicaloptions.com/hiv
More informationPediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV. Ernesto Parra, M.D., M.P.H.
Pediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV Ernesto Parra, M.D., M.P.H. Adjunct Associate Professor UTHSCSA Department of Pediatrics and Family and Community
More informationPrinciples of Antiretroviral Therapy
Principles of Antiretroviral Therapy Ten Principles of Antiretroviral Therapy Skills Building Workshop: Clinical Management of HIV Infection and Antiretroviral Therapy, 11 th ICAAP, November 21st, 2011,
More informationAre the current doses of ARV correct. Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine
Are the current doses of ARV correct Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine Can we lower doses of HIV meds safely? Consensus Panel in Alexandria
More informationHIV infection and Primary Care. HIV Care in /30/2013. It s not the AIDS of 85. Stephen Raffanti MD MPH Vanderbilt University School of Medicine
HIV infection and Primary Care Stephen Raffanti MD MPH Vanderbilt University School of Medicine HIV Care in 2013 Chronic lifelong treatment with all the associated issues: medication tolerability medication
More informationPharmacology Update Alice Tseng, Pharm.D., FCSHP Vancouver May 11, 2005
Pharmacology Update 2005 Alice Tseng, Pharm.D., FCSHP Vancouver May 11, 2005 I m having a Maalox moment!!! Gastric Hypoacidity in HIV 20% incidence in HIV (unrelated to CD 4 ) Antacids, ddi tablets, H2-blockers
More informationWhat's new in the WHO ART guidelines How did markets react?
WHO 2013 ARV Guidelines What's new in the WHO ART guidelines How did markets react? Dr. J. Perriëns Coordinator, HIV Technology and Commodities HIV department, WHO, Geneva When to start in adults Starting
More informationDIAGNOSING AND MANAGING TREATMENT FAILURE. Dr. Jeremy Nel Department of Infectious Diseases Helen Joseph Hospital
DIAGNOSING AND MANAGING TREATMENT FAILURE Dr. Jeremy Nel Department of Infectious Diseases Helen Joseph Hospital VIRAL LOAD IS EVERYTHING (KINDA ) WHY DOES HIV DEVELOP (SO MUCH) RESISTANCE? Just how much
More informationSupplementary information
Supplementary information Dose-response Curve Slope Sets Class-Specific Limits on Inhibitory Potential of Anti-HIV Drugs Lin Shen 1,2, Susan Peterson 1, Ahmad R. Sedaghat 1, Moira A. McMahon 1,2, Marc
More informationImproving PI drug resistance scores. Jens Verheyen, MD Institute of Virology University Duisburg-Essen
Improving PI drug resistance scores Jens Verheyen, MD Institute of Virology University Duisburg-Essen Overview Why can all PI drug resistance scores be improved? Do we still need to improve PI drug resistance
More informationFirst-Line Antiretroviral Therapy for Treatment and Prevention:
First-Line Antiretroviral Therapy for Treatment and Prevention: The Past, Present and Future Best Options Joel Gallant, MD, MPH Johns Hopkins University School of Medicine IAS-USA Guidelines 7/2008: When
More informationVirological suppression and PIs. Diego Ripamonti Malattie Infettive - Bergamo
Virological suppression and PIs Diego Ripamonti Malattie Infettive - Bergamo Ritonavir-boosted PIs Boosted PIs: 3 drugs in one The intrinsic antiretroviral activity Viral suppression and high baseline
More informationBHIVA Best of CROI Feedback Meetings. London Birmingham North West England Cardiff Gateshead Edinburgh
BHIVA Best of CROI Feedback Meetings London Birmingham North West England Cardiff Gateshead Edinburgh BHIVA Best of CROI Feedback Meetings 2010 ANTIRETROVIRAL TREATMENT STRATEGIES AND NEW DRUGS A5202:
More information2 nd Line Treatment and Resistance. Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012
2 nd Line Treatment and Resistance Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012 Overview Basics of Resistance Treatment failure Strategies to manage treatment failure Mutation Definition: A change
More informationBon Usage des Antirétroviraux dans l Infection par le VIH
Bon Usage des Antirétroviraux dans l Infection par le VIH Pr. Jean-Michel Molina CHU St Louis, Assistance Publique Hôpitaux de Paris, INSERM U941 et Université Paris 7 Diderot, France 1 Liens d Intérêt
More information2/10/2015. Switching from old regimens. HIV treatment revision: As simple as old versus new? What is an old regimen? What is an old regimen?
Switching from old regimens David Nolan Department of Immunology, Royal Perth Hospital, Western Australia Institute for Immunology and Infectious Diseases, Murdoch University, Western Australia What is
More informationWhat are the most promising opportunities for dose optimisation?
What are the most promising opportunities for dose optimisation? Andrew Hill Liverpool University, UK Global Financial Crisis How can we afford to treat 15-30 million people with HIV in the future? Lowering
More informationPharmacological considerations on the use of ARVs in pregnancy
Pharmacological considerations on the use of ARVs in pregnancy 11 th Residential Course on Clinical Pharmacology of Antiretrovirals Torino, 20-22 January 2016 Prof. David Burger, PharmD, PhD david.burger@radboudumc.nl
More informationWhole genome deep sequencing of HIV reveals extensive multi-class drug resistance in Nigerian patients failing first-line antiretroviral therapy
Whole genome deep sequencing of HIV reveals extensive multi-class drug resistance in Nigerian patients failing first-line antiretroviral therapy K El Bouzidi 1,, RP Datir 1, V Kwaghe 3, S Roy 1, D Frampton
More informationWhen to start, when to switch ART and monitoring of ARV side effects
When to start, when to switch ART and monitoring of ARV side effects Thanomsak Anekthananon, MD Faculty of Medicine Siriraj Hospital September 4, 2009 Recommended Websites Free e-book: HIV Medicine 2007
More informationEuropean Guidelines. for the Clinical Management and Treatment of HIV Infected Adults
European Guidelines for the Clinical Management and Treatment of HIV Infected Adults 2005 These Euroguidelines result from the comparison of guidelines from several European countries and from a discussion
More informationSelected Issues in HIV Clinical Trials
Selected Issues in HIV Clinical Trials Judith S. Currier, M.D., MSc Professor of Medicine Division of Infectious Diseases University of California, Los Angeles Issues Evolving Global and Domestic Epidemic
More informationLa terapia dell infezione da HIV: passato, presente e futuro.
1 st Infectivology Today Paestum (SA) 14-15 maggio 2004 La terapia dell infezione da HIV: passato, presente e futuro. Prof. Adriano Lazzarin Università Vita-Salute San Raffaele, Milano Scuola di Specializzazione
More informationART for HIV Prevention:
ART for HIV Prevention: KENNETH H. MAYER, M.D. Brown University/The Fenway Institute August 22, 2009 APPROACHES TO PREVENT HIV TRANSMISSION DECREASE SOURCE OF INFECTION Barrier Protection Treat STI Antiretroviral
More informationDoes Resistance Still Matter? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School
Does Resistance Still Matter? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosure The speaker serves as a consultant to, and has received
More informationFriday afternoon Programme
Friday afternoon Programme Pharmacology and TDM Dr Marta Boffito Consultant Physician, C&W Resistance to new anti-retrovirals Dr Steve Taylor Consultant Physician, Birmingham HIVPA Annual Conference 2008
More informationProfessor Jeffery Lennox
BHIVA AUTUMN CONFERENCE 2014 Including CHIVA Parallel Sessions Professor Jeffery Lennox Emory University School of Medicine Atlanta, Georgia, USA 9-10 October 2014, Queen Elizabeth II Conference Centre,
More informationBHIVA Clinical Audit. Management of patients who switch therapy; re-audit of patients starting therapy from naïve
BHIVA Clinical Audit Management of patients who switch therapy; re-audit of patients starting therapy from naïve 1 2004-5 5 audit projects Reporting now:! Survey and case note review of patients switching
More informationHistory (August 2010) Therapy for Experienced Patients. History (September 2010) History (November 2010) 12/2/11
(August 2010) Therapy for Experienced Patients Hiroyu Hatano, MD, MHS Assistant Professor of Medicine University of California San Francisco Medical Management of AIDS December 2011 42M HIV (CD4=450, VL=6250,
More information2009 Recommendations for Antiretroviral Therapy in Adults and Adolescents. When to Start and What ART to Use in 1 st and 2 nd Line December 2009
2009 Recommendations for Antiretroviral Therapy in Adults and Adolescents When to Start and What ART to Use in 1 st and 2 nd Line December 2009 Historic Evolution of CD4 Criteria for ART Initiation in
More informationFat redistribution on ARVs: dogma versus data
Fat redistribution on ARVs: dogma versus data Gary Maartens Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN KAAPSTAD Half of what we are going to teach
More informationSelected Issues in HIV Clinical Trials
Selected Issues in HIV Clinical Trials Judith S. Currier, M.D., MSc Professor of Medicine Division of Infectious Diseases University of California, Los Angeles Issues Evolving Global and Domestic Epidemic
More informationHIV in in Women Women
HIV in Women Susan L. Koletar, MD The Ohio State University How Many of These Women Have HIV? Answer: I don t really know Google Search: Photos of Groups of Women Pub Med Search: HIV and Women 22,732
More informationTunisian recommendations on ART : process and results
Second Arab Congress of Clinical Microbiology and Infectious Diseases May 24-26, 2012. Tunisian recommendations on ART : process and results M. BEN MAMOU UNAIDS Email: BenmamouM@unaids.org M. CHAKROUN
More informationThis graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts
1 2 This graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts decreased. This period of acute infection or serocnversion
More informationIntegrase Strand Transfer Inhibitors on the Horizon
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Integrase Strand Transfer Inhibitors on the Horizon David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, University of Washington Presentation
More informationPediatric HIV Update NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Pediatric HIV Update Christian B. Ramers, MD, MPH Assistant Medical Director, Family Health Centers of San Diego HIV/HCV Distance Education Specialist - NWAETC,
More informationProfessor José Arribas
19 th Annual Conference of the British HIV Association (BHIVA) Professor José Arribas Hospital La Paz, Madrid, Spain 16-19 April 2013, Manchester Central Convention Complex Can we live without nucleosides?
More informationEfficacy and Safety of Doravirine 100mg QD vs Efavirenz 600mg QD with TDF/FTC in ART-Naive HIV-Infected Patients: Week 24 Results
Efficacy and Safety of Doravirine 1mg QD vs Efavirenz 6mg QD with TDF/FTC in ART-Naive HIV-Infected Patients: Week 24 Results Jose M. Gatell, Francois Raffi, Andreas Plettenberg, Don Smith, Joaquin Portilla,
More informationChallenges in the management of treatment-experienced patients in Sub- Saharan Africa: Clinical Perspective
Challenges in the management of treatment-experienced patients in Sub- Saharan Africa: Clinical Perspective Dr. Patricia Aladi Agaba Senior Lecturer, Department of Family Medicine, University of Jos Honorary
More informationStructured Treatment Interruption in HIV Positive Patients. Leah Jackson, BScPhm Pharmacy Resident HIV Rotation January 23, 2007
Structured Treatment Interruption in HIV Positive Patients Leah Jackson, BScPhm Pharmacy Resident HIV Rotation January 23, 2007 Objectives To become re-acquainted with the basics of HAART for HIV infection
More informationResistance Workshop. 3rd European HIV Drug
3rd European HIV Drug Resistance Workshop March 30-April 1 st, 2005 Christine Hughes, PharmD Clinical Associate Professor Faculty of Pharmacy & Pharmaceutical Sciences University of Alberta Tenofovir resistance
More informationART and Prevention: What do we know?
ART and Prevention: What do we know? Biomedical Issues Trip Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Cornell Medical College New York City ART for Prevention:
More informationNorthwest AIDS Education and Training Center Educating health care professionals to provide quality HIV care
Northwest AIDS Education and Training Center Educating health care professionals to provide quality HIV care www.nwaetc.org The Northwest AIDS Education and Training Center (NW AETC), located at the University
More informationThe New Agents: Management of Experienced Patients and Resistance. Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine
The New Agents: Management of Experienced Patients and Resistance Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine T.D. 45 year old man with HIV infection diagnosed in 2000 On multiple
More informationRajesh T. Gandhi, M.D.
HIV Treatment Guidelines: 2010 Rajesh T. Gandhi, M.D. Case 29 yo M with 8 weeks of cough and fever. Diagnosed with smear-positive pulmonary TB. HIV-1 antibody positive. CD4 count 361. HIV-1 RNA 23,000
More informationART Treatment. ART Treatment
Naïve Experienced Strategies ARV in pregnancy ART Treatment Naïve studies: ART Treatment Abstract 37 Atazanavir/r vs Lopinavir/r: Castle study Abstract 774 Kivexa vs Truvada: HEAT study Abstract 775 Lopinavir/r
More informationMDR TB/HIV INTEGRATION MDR TB WORKSHOP 18 SEPTEMBER 2015
MDR TB/HIV INTEGRATION MDR TB WORKSHOP 18 SEPTEMBER 2015 HIV & MDR :Impact of early ART initiation Adjusted HR: 0.14; p = 0.042 86% reduction in mortality with ART Initiation during MDR-TB treatment 2015
More informationPaediatric Infectious Diseases Unit, Red Cross War Memorial Children s Hospital & University of Cape Town
A Public Sector Antiretroviral Treatment Programme for Treatment-Experienced Children and Adolescents in the Western Cape Province of South Africa Using Darunavir/Ritonavir-, Raltegravir- and Etravirine-Containing
More informationAnumber of clinical trials have demonstrated
IMPROVING THE UTILITY OF PHENOTYPE RESISTANCE ASSAYS: NEW CUT-POINTS AND INTERPRETATION * Richard Haubrich, MD ABSTRACT The interpretation of a phenotype assay is determined by the cut-point, which defines
More informationDRUGS IN PIPELINE. Pr JC YOMBI UCL-AIDS REFERENCE CENTRE BREACH Sept 27, 2015
DRUGS IN PIPELINE Pr JC YOMBI UCL-AIDS REFERENCE CENTRE BREACH Sept 27, 2015 N(t)RTI The Development of TAF TAF Delivers the High Potency of TDF While Minimizing Off- Target Kidney and Bone Side Effects
More informationNew Hope for Treatment Experienced HIV (+) Patients. Treatment Experienced. Drug Resistance: Estimated Prevalence. Patients in the US- Estimate
New Hope for Treatment Experienced HIV (+) Patients Nelson Vergel www.salvagetherapies.org HIV/AIDS Pandemic 23: Adults and Children Living With HIV/AIDS 47% of Cases are Women 15.6% Eastern Europe Western
More informationQuick Reference Guide to Antiretrovirals. Guide to Antiretroviral Agents
Author: Malte Schütz, MD June 1, 2002 Quick Reference Guide to Antiretrovirals Regular updates to this publication are posted on the Medscape Web site at http://hiv.medscape.com/updates/quickguide. Please
More informationPediatric Antiretroviral Resistance Challenges
Pediatric Antiretroviral Resistance Challenges Thanyawee Puthanakit, MD The HIVNAT, Thai Red Cross AIDS research Center The Research Institute for Health Science, Chiang Mai University Outline The burden
More informationStatistical issues in HIV trial design. Andrew Hill Senior Visiting Research Fellow Liverpool University
Statistical issues in HIV trial design Andrew Hill Senior Visiting Research Fellow Liverpool University Type 1 error It is statistically significant! (after 100 different statistical tests) Type 1 error:
More informationTHE SOUTH AFRICAN ANTIRETROVIRAL TREATMENT GUIDELINES 2010
THE SOUTH AFRICAN ANTIRETROVIRAL TREATMENT GUIDELINES 2010 The South African Antiretroviral Treatment Guidelines 2010 Goals of the programme Achieve best health outcomes in the most cost-efficient manner
More informationTDF containing ART: Efficacy and Safety. Dr Lloyd B. Mulenga Adult Infectious Diseases Centre University Teaching Hospital Lusaka, Zambia
TDF containing ART: Efficacy and Safety Dr Lloyd B. Mulenga Adult Infectious Diseases Centre University Teaching Hospital Lusaka, Zambia 1 Indications Treatment of HIV-1 in combination with other antiretroviral
More informationAntiretroviral Therapy
Antiretroviral Therapy Scott M. Hammer, M.D. 1986 1990 ZDV monorx 1990 1995 Alternative NRTI monorx Combination NRTI Rx Introduction of NNRTI s Antiretroviral resistance Pathogenetic concepts Evolution
More informationModule 6: ARVs in Children
Module 6: ARVs in Children Module Objectives To review the use of ARVs in children and their impact on disease progression To provide nurses with a general understanding of the differences in ARV use in
More informationIntroduction to HIV Drug Resistance. Kevin L. Ard, MD, MPH Massachusetts General Hospital Harvard Medical School
Introduction to HIV Drug Resistance Kevin L. Ard, MD, MPH Massachusetts General Hospital Harvard Medical School Objectives 1. Describe the epidemiology of HIV drug resistance in sub-saharan Africa. 2.
More informationFirst line ART Rilpirivine A New NNRTI. Chris Jack Physician, Durdoc Centre ethekwini
First line ART Rilpirivine A New NNRTI Chris Jack Physician, Durdoc Centre ethekwini Overview: Rilpirivine an option for ARV Naïve patients History Current guidelines Efficacy and Safety Tolerability /
More informationHIV - Therapy Principles
HIV - Therapy Principles Manuel Battegay and Christine Katlama Basel, Switzerland and Paris, France Disclosure MB has received honoraria for advisory board participation from Gilead, MSD, Pfizer, ViiV
More informationPerspectivesconcernantles InhibiteursNon Nucléosidiquesde la Transcriptase Inverse (INNTI)
Perspectivesconcernantles InhibiteursNon Nucléosidiquesde la Transcriptase Inverse (INNTI) Gianni Di Perri Dept. de Maladies Infectieuses Universitè de Turin Ospedale Amedeo di Savoia Fusion inhibitors
More informationOptimizing 2 nd and 3 rd Line Antiretroviral Therapy in Children and Adolescents
Optimizing 2 nd and 3 rd Line Antiretroviral Therapy in Children and Adolescents Victor Musiime, MBChB, MMED, PhD Senior Lecturer, Makerere University Investigator, Joint Clinical Research Centre (JCRC)
More informationVirological failure in children. Dr Lee Fairlie
Virological failure in children Dr Lee Fairlie Case 1 Thembi is a 34 year old female. She is HIV infected She lives in JHB and her 2 children, Lerato and Sipho live in Mpumalanga with Gogo They are both
More informationGuidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline
More informationNational AIDS Treatment Advocacy Project
National AIDS Treatment Advocacy Project T-20 (first fusion inhibitor) Nelfinavir 12 month data Latent HIV reservoir (integrated proviral DNA), CSF and protease inhibitors: preliminary data (ritonavir/saquinavir
More informationPediatric Antiretroviral Therapy
Update on Pediatric Antiretroviral Therapy Lynne M. Mofenson, M.D. Pediatric, Adolescent and Maternal AIDS Branch National Institute of Child Health and Human Development National Institutes of Health
More information/AIDS HIV/ HIV Overview. Nelson L. Michael, MD, PhD Division of Retrovirology Walter Reed Army Institute of Research US Military HIV Research Program
/AIDS HIV/ HIV Overview Nelson L. Michael, MD, PhD Division of Retrovirology Walter Reed Army Institute of Research US Military HIV Research Program www.hivresearch.org 1 WRAIR Tropical Medicine Course
More informationCongress report: XV Congreso Panamericano De Infectología the PROGRESS Study
HAART, HIV correlated pathologies and other infections Marco Borderi*, Adriano Lazzarin Congress report: XV Congreso Panamericano De Infectología the PROGRESS Study Infectious Diseases Unit S. Orsola Hospital
More informationWhen to Start ART. Reduction in HIV transmission. ? Reduction in HIV-associated inflammation and associated complications» i.e. CV disease, neuro, etc
When to Start ART Exact CD4 count at which to initiate therapy not known, but evidence points to starting at higher counts Current recommendation: ART for all patients with CD4 count of
More informationSupplemental Digital Content 1. Combination antiretroviral therapy regimens utilized in each study
Supplemental Digital Content 1. Combination antiretroviral therapy regimens utilized in each study Study Almeida 2011 Auld 2011 Bassett 2012 Bastard 2012 Boulle 2008 (a) Boulle 2008 (b) Boulle 2010 Breen
More information0% 0% 0% Parasite. 2. RNA-virus. RNA-virus
HIV/AIDS and Treatment Manado, Indonesia 16 november HIV [e] EDUCATION HIV is a 1. DNA-virus 2. RNA-virus 3. Parasite 0% 0% 0% DNA-virus RNA-virus Parasite HIV HIV is a RNA-virus. HIV is an RNA virus which
More informationHIV Overview. Mary Marovich, MD, DTMH Division of Retrovirology Walter Reed Army Ins?tute of Research US Military HIV Research Program
HIV Overview Mary Marovich, MD, DTMH Division of Retrovirology Walter Reed Army Ins?tute of Research US Military HIV Research Program www.hivresearch.org 1 Outline HIV Virology, Transmission, and Pathogenesis
More informationIndividual Study Table Referring to the Dossier SYNOPSIS. Final Clinical Study Report for Study AI424138
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Reyataz Name of Active Ingredient: Atazanavir () Individual Study Table Referring to the Dossier (For National Authority Use Only)
More informationTreatment of HIV-1 in Adults and Adolescents: Part 2
Treatment of HIV-1 in Adults and Adolescents: Part 2 Heather E. Vezina, Pharm.D. University of Minnesota Laboratory Medicine & Pathology Experimental & Clinical Pharmacology wynnx004@umn.edu Management
More information